Amgen (AMGN) is higher in Wednesday trading as investors digest a new late-stage pipeline win: positive topline Phase 3 results for subcutaneous Tepezza in adults with moderate-to-severe active thyroid eye disease. A formulation and delivery upgrade for a marketed franchise can materially expand the addressable patient pool by improving convenience and infusion burden, which tends to matter for physician adoption and patient adherence. (amgen.com)

The company said the Phase 3 study for the subcutaneous version of Tepezza met its topline objective in the target thyroid eye disease population, a readout that strengthens confidence in lifecycle management for a key product added through the Horizon acquisition. With IV Tepezza already established in the market, a successful subcutaneous option can be positioned as a next-step product enhancement rather than a de novo commercial build, which investors typically reward with higher probability-weighted revenue assumptions. (amgen.com)

The rally is also getting support from recent analyst target increases that add near-term narrative momentum. Royal Bank of Canada lifted its price target to $370 and kept an Outperform stance, helping frame the pipeline update as incremental upside rather than a one-off headline. (nationaltoday.com)

Key follow-through items include regulatory filing timing for the subcutaneous Tepezza program and how Amgen plans to sequence launches and label strategy versus the existing IV product. Separately, investors are monitoring whether upcoming 2026 company guidance milestones and pipeline execution keep supporting the current multiple as the market balances new-product growth with patent-cycle and pricing-policy risks. (amgen.com)